[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642884":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":28,"locations":34,"responsibleParty":47,"collaborators":27,"id":51,"slug":27,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":27,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":27,"overallStatus":70,"whyStopped":27,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Taizhou Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intraosseous TXA Group","EXPERIMENTAL","Knee: Before tourniquet release, a dedicated intraosseous needle was inserted into the proximal tibial cancellous bone adjacent to the tibial tubercle, and tranexamic acid (15 mg\u002Fkg) was administered intraosseously.\n\nHip: Before skin incision, a dedicated intraosseous needle was inserted into the proximal femoral cancellous bone adjacent to the greater trochanter, and tranexamic acid (15 mg\u002Fkg) was administered intraosseously",[13],"Drug: Tranexamic Acid",{"label":15,"type":16,"description":17,"interventionNames":18},"Intravenous TXA Group","ACTIVE_COMPARATOR","Participants receive intravenous tranexamic acid administration at a dose of 15 mg\u002Fkg during joint arthroplasty.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Tranexamic Acid","Tranexamic acid was administered at a dose of 15 mg\u002Fkg during joint arthroplasty. Depending on study group assignment, the drug was administered either through peripheral intravenous injection or intraosseous injection into the proximal tibial or proximal femoral cancellous bone using a dedicated intraosseous needle.",[9,15],[26],"TXA",null,[29],{"name":30,"role":31,"phone":32,"phoneExt":27,"email":33},"Hua Luo, Dr.","CONTACT","0576-85190460","luohua66ry@163.com",[35],{"facility":36,"status":27,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":27},"No. 150 Ximen Road","Linhai","Zhejiang","317000","China",{"type":42,"coordinates":43},"Point",[44,45],120.97629,30.17415,{"lat":45,"lon":44},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"SPONSOR_INVESTIGATOR","Hua Luo","Doctor","100642884",false,"NCT07614087","Plasma Concentrations of Intraosseous Versus Intravenous Tranexamic Acid in Joint Arthroplasty","A Prospective Randomized Controlled Trial Comparing Plasma Concentrations of Intraosseous and Intravenous Tranexamic Acid in Patients Undergoing Joint Arthroplasty","IO TXA","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Patients scheduled for primary total hip arthroplasty or total knee arthroplasty\n* Diagnosis of osteoarthritis\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Preoperative hemoglobin ≥ 9 g\u002FdL\n* Ability to provide written informed consent\n* Willingness to comply with postoperative follow up and study procedures\n\nExclusion Criteria:\n\n* History of coagulation disorders or bleeding disorders\n* History of pulmonary embolism\n* Known allergy to tranexamic acid\n* Pregnancy or breastfeeding\n* Severe hepatic or renal dysfunction\n* Preoperative anticoagulant therapy\n* Body mass index \\> 40 kg\u002Fm²\n* Body weight \\\u003C 45 kg","ALL","18 Years","80 Years",{"count":62,"type":63},80,"ESTIMATED","INTERVENTIONAL",[66],"PHASE4","This prospective randomized controlled trial aims to compare the pharmacokinetic profiles of intraosseous and intravenous tranexamic acid administration in patients undergoing primary total joint arthroplasty. Eligible patients undergoing total hip or total knee arthroplasty will be randomly assigned to receive tranexamic acid either through intraosseous injection or intravenous injection at a dose of 15 mg\u002Fkg. Blood samples will be collected at predefined time points to evaluate plasma concentrations and pharmacokinetic characteristics of tranexamic acid. Secondary outcomes include coagulation function, intraoperative blood loss, transfusion rate, and hemoglobin changes. The study aims to provide evidence regarding the pharmacokinetic characteristics and clinical feasibility of intraosseous tranexamic acid administration in joint arthroplasty.",[69],"Osteoarthritis","NOT_YET_RECRUITING","2026-06-09",{"date":73,"type":74},"2026-06-11","ACTUAL",{"date":76,"type":63},"2026-05-27",{"date":78,"type":63},"2026-12-30",{"name":49,"class":6},1]